CDMO News and Research

RSS

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing.

14 Jul 2026

Evonik invests US$100 million to upgrade its U.S. drug substance contract manufacturing site

Evonik is making a significant investment to strengthen manufacturing capabilities at its Lafayette (Tippecanoe), Indiana facility.

From Evonik 14 Jul 2026

Insilico Medicine founder to highlight sustainable longevity at BIO Asia-Taiwan

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend BIO Asia-Taiwan, which will be held from July 15 to 19 in Taiwan, China.

11 Jul 2026

Hovione and IDC Intranasal Drug Delivery Platform available for commercial partnerships

Hovione, a global integrated specialist CDMO, and Industrial Design Consultancy Ltd (IDC), an international product development company, today announced that their Intranasal Drug Delivery Platform has reached a new milestone, with its lead single-use nasal dry powder device now available for commercial partnerships.

From Hovione 11 May 2026

Northumbria University spinout earns CE mark for breath sampling device

A medical device company spun out of Northumbria University has reached a significant milestone — receiving CE marking for a breath sampling platform that peer-reviewed research has demonstrated can reliably collect saliva-free exhaled breath condensates (EBC) from the deep lung, making it the first technology of its type to achieve this distinction.

2 Apr 2026

LGM Pharma expands U.S. manufacturing, bringing total investment to $15M across Texas and Colorado sites

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug product lifecycle, today announced the second phase of its CDMO growth strategy, committing an additional $9 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado.

From LGM Pharma 19 Mar 2026

Sartorius launches next-generation platform to boost efficiency in cell therapy production

The life science group Sartorius is launching an integrated system for the production and quality control (QC) of autologous cell therapies.

From Sartorius 18 Mar 2026

mAbxience selects Genedata Bioprocess to automate end-to-end CDMO workflows

Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations.

From Genedata AG 11 Mar 2026

AI model accelerates antibody production and clone selection

As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, autoimmune diseases, and many other conditions.

9 Feb 2026

New partnership aims to expand global access to sickle cell gene therapy

Caring Cross, a 501(c)(3) non-profit dedicated to improving access to advanced therapies, and Boston Children's Hospital today announced a collaboration to provide a sustainable, affordable pathway for patients to access stem cell gene therapies for the treatment of Sickle Cell Disease (SCD).

22 Jan 2026

One‑Step ADC Manufacturing Reaches 95% Yield in Under One Hour, BioDlink White Paper Reveals

A new white paper from BioDlink, From Complexity to Consistency: How CDMOs Can Unlock One-Step, High-Yield and Homogeneous ADC Manufacturing for Next-Gen Oncology, reveals an advancement in antibody-drug conjugate (ADC) manufacturing

From BioDlink 15 Jan 2026

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

From Rentschler Biopharma SE 2 Dec 2025

PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies

PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP manufacturing, aiming to accelerate non-viral cell and gene therapies for the benefit of patients.

From PlasmidFactory GmbH 9 Oct 2025

BioDlink Commends Junshi Biosciences as its Bispecific ADC Candidate JS212 Receives IND Approval

BioDlink, a leading global CDMO, extends its congratulations to Junshi Biosciences, on receiving Investigational New Drug (IND) approval

From BioDlink 12 Sep 2025

BioDlink expands ecosystem alliance to empower biotech innovators worldwide

As BioDlink, a leading global CDMO, affirms its commitment to strategic alliances to support biotech innovation worldwide as it marks 15 years of operations.

From BioDlink 5 Sep 2025

The Microsphere Summit is Back

Attend the 2025 Microsphere Summit to connect with leaders in drug delivery and manufacturing, focusing on particle size control and therapeutic advancements.

From Powder Systems 5 Aug 2025

Fujifilm rebrands Life Sciences Companies to strengthen position as strategic partners for life, offering end-to-end solutions

FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, today announced new names and identities as part of a strategic positioning effort.

3 Jun 2025

Waters integrates Multi-Angle Light Scattering Detectors with empower software for improved biologics quality control and simplified regulatory compliance

Waters Corporation today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio.

From Waters Corporation 7 May 2025

BIOVECTRA is honored with 2025 CDMO Leadership Award for biologics

BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics.

13 Mar 2025

LGM Pharma invests $6 M in U.S. drug manufacturing capabilities for liquids, suspensions, semi-solids, and suppositories

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy.